

Omaha Metropolitan Healthcare Coalition



Table 1. CDC Recommended COVID-19 Vaccine Schedule For People Who Are *NOT* Immunocompromised

Ages 6 months through 11 years						
Primary Series Manufacturer	Age Group	# Primary Doses	Recommended <i>Monovalent</i> Booster (# doses)	Interval between primary doses 1 and 2	Interval between primary doses 2 and 3	Interval between primary series and booster
Moderna	6 months – 5 years	2	N/A	4 – 8 weeks	N/A	N/A
	6 – 11 years	2	N/A	4 – 8 weeks	N/A	N/A
Pfizer-BioNTech	6 months – 4 years	3	N/A	3 – 8 weeks	At least 8 weeks	N/A
	5 – 11 years	2	Pfizer-BioNTech (1 dose)	3 – 8 weeks	N/A	At least 5 months
Ages 12 years through 17 years						
Primary Series Manufacturer	Age Group	# Primary Doses	Recommended <i>Bivalent</i> Booster (# doses) †	Interval between primary doses 1 and 2	Interval between primary doses 2 and 3	Interval between primary series and booster‡
Moderna	12 – 17 years	2	Pfizer-BioNTech (1 dose)	4 – 8 weeks	N/A	At least 2 months
Pfizer-BioNTech		2		3 – 8 weeks	N/A	At least 2 months
Novavax		2		3 – 8 weeks	N/A	At least 2 months
Ages ≥ 18 years						
Primary Series Manufacturer	Age Group	# Primary Doses	Recommended <i>Bivalent</i> Booster (# doses) †	Interval between primary doses 1 and 2	Interval between primary doses 2 and 3	Interval between primary series and booster‡
Moderna	≥ 18 years	2	Pfizer-BioNTech OR Moderna (1 dose)	4 – 8 weeks	N/A	At least 2 months
Pfizer-BioNTech		2		3 – 8 weeks	N/A	At least 2 months
Novavax		2		3 – 8 weeks	N/A	At least 2 months
Previously Received Janssen		1		N/A	N/A	At least 2 months

Table 2. CDC Recommended COVID-19 Vaccine Schedule For People Who Are Moderately Or Severely Immunocompromised

Ages 6 months through 11 years						
Primary Series Manufacturer	Age Group	# Primary Doses	Recommended <i>Monovalent</i> Booster (# doses)	Interval between primary doses 1 and 2	Interval between primary doses 2 and 3	Interval between primary series and booster
Moderna	6 months – 5 years	3	N/A	4 weeks	At least 4 weeks	N/A
	6 – 11 years	3	N/A	4 weeks	At least 4 weeks	N/A
Pfizer-BioNTech	6 months – 4 years	3	N/A	3 weeks	At least 8 weeks	N/A
	5 – 11 years	3	Pfizer-BioNTech (1 dose)	3 weeks	At least 4 weeks	At least 3 months
Ages 12 years through 17 years						
Primary Series Manufacturer	Age Group	# Primary Doses	Recommended <i>Bivalent</i> Booster (# doses) †	Interval between primary doses 1 and 2	Interval between primary doses 2 and 3	Interval between primary series and booster‡
Moderna	12 – 17 years	3	Pfizer-BioNTech (1 dose)	4 weeks	At least 4 weeks	At least 2 months
Pfizer-BioNTech		3		3 weeks	At least 4 weeks	At least 2 months
Novavax		2		3 weeks	N/A	At least 2 months
Ages ≥ 18 years						
Primary Series Manufacturer	Age Group	# Primary Doses	Recommended <i>Bivalent</i> Booster (# doses) †	Interval between primary doses 1 and 2	Interval between primary doses 2 and 3	Interval between primary series and booster‡
Moderna	≥ 18 years	3	Pfizer-BioNTech OR Moderna (1 dose)	4 weeks	At least 4 weeks	At least 2 months
Pfizer-BioNTech		3		3 weeks	At least 4 weeks	At least 2 months
Novavax		2		3 weeks	N/A	At least 2 months
Previously Received Janssen		2		4 weeks; Dose 2 mRNA vaccine	N/A	At least 2 months

†For people ages ≥ 12 years, 1 bivalent mRNA booster dose is recommended after completion of any FDA-approved or FDA-authorized monovalent primary series or previously received monovalent booster dose(s). The bivalent Moderna booster dose is authorized for people ages ≥ 18 years; the bivalent Pfizer-BioNTech booster dose is authorized for people ages ≥ 12 years.

‡The bivalent booster dose is administered at least 2 months after completion of the primary series. For people who previously received a monovalent booster dose(s), the bivalent booster dose is administered at least 2 months after the last monovalent booster dose.

References:

- Interim Clinical Considerations for Use of COVID-19 Vaccines Currently Approved or Authorized in the United States. Centers for Disease Control and Prevention. Last Updated: 9/2/2022; Accessed: 9/6/2022. Available at: <https://www.cdc.gov/vaccines/covid-19/clinical-considerations/interim-considerations-us.html#table-02>
- COVID-19 Vaccination Schedule At-A-Glance. Centers for Disease Control and Prevention. Last updated: 9/2/2022; Accessed: 9/6/2022. Available at: <https://www.cdc.gov/vaccines/covid-19/downloads/COVID-19-vacc-schedule-at-a-glance-508.pdf>